NanoViricides Announces That Its Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus And Other Ebola Viruses In Democratic Republic Of Congo Is Scheduled To Begin Next Week
Clinical trial is scheduled to start at an Ebola Treatment Center in the Ituri province."NV-387 being an oral drug with broad-spectrum antiviral properties, everyone is rooting for it and hoping that it is effective
A company called NanoViricides is testing a new Ebola medicine next week. When a medicine enters real human testing, it shows the company is making progress on something important.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.